Pregabalin Capsule
Product Images NDC 71205-396

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-396). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71205-396-60 (Pregabalin Caps 150mg 90s Count)

71205-396-60 (Pregabalin Caps 150mg 90s Count)
This is a medication package of Pregabalin 150mg (NDC 71205-396-60) containing 60 capsules made by ScieGen Pharmaceuticals, Inc. The capsules are hard gelatin and filled with white to off white powder. Each capsule is imprinted with "SG" on the cap and "354" on the body with black ink. The lot number is 00000 and the expiration date is 00/00/00. The medication guide should be provided to each patient. It is for prescription use only. Store at 25°C (77°F) and keep out of reach of children.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The text is a mixture of numbers and characters that do not form a coherent description. Therefore, the description is not available.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
This text likely represents data related to different medications and their impact on patient pain relief. It includes various doses of "Pregatalin" and "Pregabalin", along with a measure of improvement in pain from a baseline level. The first line appears to show the percentage of patients who experienced improvement, while subsequent lines indicate different dosage amounts and frequencies. The last line likely shows a time measurement or duration of the study.*
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
The text appears to be a table or a graph with medication dosages and their corresponding effects. It also mentions "statistically significant vs. placebo." Without further context, it is difficult to provide a specific description.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The text shows a graph that compares the percentage of improvement in pain from baseline for patients taking Pregabalin at daily doses of 300mg and 450mg, as well as for patients taking a placebo. The horizontal axis measures improvement in pain from baseline, while the vertical axis shows the percentage of patients. The graph shows a significant increase in pain relief for patients taking Pregabalin compared to those taking a placebo, with a higher percentage of patients experiencing improvement at the 450mg dose compared to the 300mg dose.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a table that shows the percentage of subjects without LTR (not clear what LTR stands for) for a drug called "Progabain" and a placebo over a period of 120 days. The percentages range from 0% to 100%.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
The text is describing a chart or graph showing the percentage of subjects who have improved from "Bassin to ek 12 BOCF". There is no actual data provided and it is not clear what "Bassin" or "ek" refer to.*
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This appears to be a formula used for calculating creatinine clearance, a measure of kidney function. The formula involves subtracting the patient's age from 140 and multiplying the result by their weight in kilograms, then multiplying that by a correction factor of 0.85 for female patients. The result is then multiplied by their serum creatinine level in milligrams per deciliter, and divided by 72 to obtain their estimated creatinine clearance in milliliters per minute.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.